论文部分内容阅读
目的评价西地那非在干预男性肾移植受者手术前后勃起功能时的有效性及安全性。方法选取年龄23～58岁、移植肾存活1年以上、血肌酐在移植后1年内维持在150μmol/L以下的成年男性肾移植受者41人,所有患者在血液透析期间及移植后均口服西地那非两月,对患者血液透析期间、移植后6月及1年的勃起功能进行调查(依据国际问卷表IIEF-5),记录其各个时段的环孢素浓度、血压及血肌酐。结果肾移植前与移植后6月及1年患者的ED发生率相比,有显著性差异(P<0.05);不论血液透析期间还是移植后,西地那非治疗后的勃起功能与服药前勃起功能相比,有显著性差异(P<0.05);不论血液透析期间还是移植后,西地那非治疗后的环孢素浓度、血压及肌酐与服药前组相比,无显著性差异(P>0.05)。结论肾移植后,患者的勃起功能得到了改善;不论对于尿毒症血液透析患者,还是肾移植受者,西地那非都可以改善患者的勃起功能,而且西地那非的应用具有安全性。
Objective To evaluate the efficacy and safety of sildenafil in the intervention of erectile function in male renal transplant recipients. Methods Thirty-one adult male renal transplant recipients aged 23-58 years old with graft survival of more than 1 year and serum creatinine maintained below 150μmol / L within 1 year after transplantation were enrolled. All patients were orally administered during hemodialysis and after transplantation In the two-month indinavir erectile dysfunction during hemodialysis, 6 months and 1 year after transplantation (according to the International Questionnaire IIEF-5), the cyclosporine concentration, blood pressure and serum creatinine were recorded at various intervals. Results There was a significant difference in the incidence of ED between before transplantation and 6 months and 1 year after transplantation (P <0.05). Both hemodialysis and sildenafil after transplantation did not affect the erectile function before and after treatment Erectile function compared with the significant difference (P <0.05); regardless of hemodialysis during or after transplantation, sildenafil treatment after cyclosporine concentration, blood pressure and creatinine before taking the group compared to no significant difference ( P> 0.05). Conclusion After erection, the erectile function of the patients is improved. Sildenafil can improve the erectile function of uremic hemodialysis patients and renal transplant recipients, and the application of sildenafil is safe.